Spaces:
Running
Running
File size: 5,418 Bytes
98be852 db137bd 98be852 db137bd 98be852 153a479 98be852 9995f5e cfca820 98be852 bf52997 | 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 | {
"spec": "v1.1",
"categories": [
{
"id": "A",
"name": "ํก์",
"en": "Absorption",
"icon": "๐ซ",
"desc": "๋จน์ ์ฝ์ด ๋ชธ ์์ผ๋ก ๋ค์ด์ค๋๊ฐ",
"planned": 8,
"boards": [
"Solubility",
"LogP",
"Caco2"
],
"desc_en": "Whether an orally dosed compound enters the body at all"
},
{
"id": "D",
"name": "๋ถํฌ",
"en": "Distribution",
"icon": "๐ฉธ",
"desc": "ํ์ก ๋จ๋ฐฑ์ง์ ๋ถ๋๊ฐ ยท ๋๊น์ง ๊ฐ๋๊ฐ",
"planned": 5,
"boards": [
"PPB",
"Vdss"
],
"desc_en": "Binding to plasma protein; passage across the blood-brain barrier"
},
{
"id": "M",
"name": "๋์ฌ",
"en": "Metabolism",
"icon": "๐ฅ",
"desc": "๊ฐ์์ ์ผ๋ง๋ ๋นจ๋ฆฌ ์ฌ๋ผ์ง๋๊ฐ ยท ์ด๋ค ํจ์๊ฐ ๊ฑด๋๋ฆฌ๋๊ฐ",
"planned": 7,
"boards": [
"CYP3A4",
"CYP2D6",
"CYP2C9"
],
"desc_en": "How quickly the liver clears it, and which enzymes act on it"
},
{
"id": "E",
"name": "๋ฐฐ์ค",
"en": "Excretion",
"icon": "๐ง",
"desc": "๋ชธ ๋ฐ์ผ๋ก ์ธ์ ๋๊ฐ๋๊ฐ",
"planned": 2,
"boards": [
"HalfLife"
],
"desc_en": "When the compound leaves the body"
},
{
"id": "T",
"name": "๋
์ฑ",
"en": "Toxicity",
"icon": "โ ๏ธ",
"desc": "์ฌ์ฅ ยท ๊ฐ ยท ๋ณ์ด์์ฑ. ์ ์ฝ์ด ๊ฐ์ฅ ๋ง์ด ์ฃฝ๋ ์๋ฆฌ",
"planned": 7,
"boards": [
"hERG",
"LD50"
],
"desc_en": "Cardiac, hepatic and mutagenic liability โ where candidates most often fail"
},
{
"id": "P",
"name": "ํจ๋ฅยท์ญ๊ฐ",
"en": "Potency",
"icon": "๐ฏ",
"desc": "ํ์ ์ ์ผ๋ง๋ ์ธ๊ฒ ๋ถ๋๊ฐ",
"planned": 4,
"boards": [
"AChE",
"MAOB",
"COX2",
"Nav17"
],
"desc_en": "How tightly a compound binds its intended target"
},
{
"id": "Z",
"name": "์ํผ์ ๋คํฑ",
"en": "Epigenetics",
"icon": "๐",
"desc": "์ ์ ์๋ฅผ ๋ฐ๊พธ์ง ์๊ณ ์ฝ๋ ๋ฐฉ์์ ๋ฐ๊พผ๋ค",
"desc_en": "Changing how genes are read without changing the genes",
"planned": 5,
"boards": [
"BRD4",
"HDAC1"
]
},
{
"id": "N",
"name": "ํต์์ฉ์ฒด",
"en": "Nuclear receptors",
"icon": "๐งฟ",
"desc": "ํธ๋ฅด๋ชฌ ์ ํธ๋ฅผ ๋ฐ์ ์ ์ ์๋ฅผ ์ผ๊ณ ๋๋ค โ ์ ๋ฐฉ์ยท์ ๋ฆฝ์ ์ ํ์ ",
"desc_en": "Hormone-driven transcription factors โ breast and prostate cancer targets",
"planned": 5,
"boards": [
"ERalpha",
"AR"
]
},
{
"id": "E2",
"name": "ํ๋กํ
์์ ",
"en": "Proteases",
"icon": "โ๏ธ",
"desc": "๋จ๋ฐฑ์ง์ ์๋ฅด๋ ํจ์ โ ์์ธ ํ์ด๋จธยทํญ์๊ณ ยทํญ๋ฐ์ด๋ฌ์ค๊ฐ ์ฌ๊ธฐ ๊ฑธ๋ฆฐ๋ค",
"desc_en": "Protein-cleaving enzymes behind Alzheimer, anticoagulant and antiviral programmes",
"planned": 6,
"boards": [
"BACE1",
"Thrombin",
"FactorXa"
]
},
{
"id": "K",
"name": "ํค๋์์ ยท์ ํ์ฑ",
"en": "Kinase & Selectivity",
"icon": "๐",
"desc": "ํค๋์์ ์๋ฐฑ ๊ฐ ์ค ์ด๋์ ๋ถ๊ณ ์ด๋๋ ํผํ๋๊ฐ",
"planned": 13,
"boards": [
"EGFR",
"JAK2",
"PI3Ka",
"FLT3",
"VEGFR2",
"CDK2",
"HER2",
"ABL1",
"BRAF",
"KIT",
"ALK",
"Selectivity"
],
"desc_en": "Which of several hundred kinases are engaged, and which are spared"
},
{
"id": "R",
"name": "์์ฉ์ฒดยทGPCR",
"en": "Receptors & GPCR",
"icon": "๐ก",
"desc": "์ธํฌ ํ๋ฉด ์์ฉ์ฒด โ ์น์ธ์ฝ ์ธ ๊ฐ ์ค ํ๋๊ฐ ์ฌ๊ธฐ๋ฅผ ๋
ธ๋ฆฐ๋ค",
"desc_en": "Cell-surface receptors โ the target class behind roughly a third of approved drugs",
"planned": 8,
"boards": [
"D2",
"HT2A",
"MuOpioid",
"KappaOpioid",
"A2A",
"CB1"
]
},
{
"id": "S",
"name": "๊ตฌ์กฐ๊ธฐ๋ฐ ๊ฒฐํฉ",
"en": "Structure-based",
"icon": "๐งฌ",
"desc": "์ด๋ค ์์ธ๋ก ๋ถ๋๊ฐ ยท ๊ทธ ์์ธ๊ฐ ๋ฌผ๋ฆฌ์ ์ผ๋ก ๋ง์ด ๋๋๊ฐ",
"planned": 4,
"boards": [],
"desc_en": "The binding pose, and whether that pose is physically admissible"
},
{
"id": "X",
"name": "์ธํฌยทํํํ",
"en": "Cell & Phenomics",
"icon": "๐ฌ",
"desc": "์ฝ์ด ์ค์ ์ธํฌ์ ๋ฌด์จ ์ง์ ํ๋๊ฐ",
"planned": 5,
"boards": [
"Phenotype"
],
"desc_en": "What a compound actually does to a living cell"
},
{
"id": "I",
"name": "ํญ๊ฐ์ผยท์ ์ธํฌ",
"en": "Anti-infective & whole-cell",
"icon": "๐ฆ ",
"desc": "๊ท ๊ณผ ๊ธฐ์์ถฉ์ด ์ค์ ๋ก ์ฃฝ๋๊ฐ โ ๋จ๋ฐฑ์ง์ด ์๋๋ผ ์๋ฌผ์ ์ฝ๋๋ค",
"desc_en": "Whether the organism actually dies โ the readout is a living cell, not a protein",
"planned": 6,
"boards": [
"Malaria",
"SEpidermidis",
"MTB",
"SAureus"
]
},
{
"id": "C",
"name": "์์ ์ธ์ค๋ฆฌ์ฝ",
"en": "Clinical in-silico",
"icon": "๐ฅ",
"desc": "์ฌ๋ ๋ชธ์์์ ๋๋ ยท ์ฝ๋ฌผ ์ถฉ๋ ยท ์ฉ๋. ๊ฒจ๋ฃฐ ํ๊ฐ ์์ง ์๋ ์๋ฆฌ",
"planned": 6,
"boards": [
"Withdrawal"
],
"desc_en": "Human exposure, drug-drug interaction and dose โ endpoints with no leaderboard yet"
},
{
"id": "G",
"name": "์์ฑยท๋ชจ๋ฌ๋ฆฌํฐ",
"en": "Generation & Modality",
"icon": "โ๏ธ",
"desc": "์๋ก ๋ง๋ค์ด ๋ด๋ ์ชฝ ยท ์๋ถ์๋ฅผ ๋์ด์๋ ์ชฝ",
"planned": 5,
"boards": [],
"desc_en": "Generating new matter, and modalities beyond small molecules"
}
]
} |